Table 1.
Clinicopathological features of the study cohort (n = 1010)
| Parameters | Number (%) |
|---|---|
| Age (year) | |
| < 40 | 133 (13.2) |
| ≥ 40 | 877 (86.8) |
| Menopause | |
| Yes | 399 (39.5) |
| No | 611 (60.5) |
| Chemotherapy cycles | |
| 3 | 29 (2.9) |
| 4 | 900 (89.2) |
| 5–8 | 81 (7.9) |
| Subtypes of cancer | |
| Ductal | 986 (97.6) |
| Lobular | 13 (1.3) |
| Others | 11 (1.1) |
| Tumor size | |
| < 2 cm | 74 (7.3) |
| 2–4 cm | 522 (51.7) |
| ≥ 4 cm | 414 (41.0) |
| Clinical nodal status | |
| Positive | 473 (46.8) |
| Negative | 537 (53.2) |
| Histological grade | |
| I | 26 (2.6) |
| II | 578 (57.3) |
| III | 130 (12.9) |
| Unknown | 276 (27.2) |
| Response evaluation | |
| pCR | 131 (13.0) |
| cPR | 574 (56.8) |
| cSD | 290 (28.7) |
| cPD | 15 (1.5) |
| Responder (pCR and cPR) | 705 (69.8) |
| Non-responder (cSD and cPD) | 305 (30.2) |
pCR pathological complete response, cPR clinical partial response, cPD clinical progressive disease, cSD clinical stable